The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer (ROC) patients.
D. Lorusso
No relevant relationships to disclose
P. Malaguti
No relevant relationships to disclose
V. Masciullo
No relevant relationships to disclose
S. Mainenti
No relevant relationships to disclose
A. di Legge
No relevant relationships to disclose
M. Ludovisi
No relevant relationships to disclose
A. Pesce
No relevant relationships to disclose
F. Mascilini
No relevant relationships to disclose
E. Fusco
No relevant relationships to disclose
G. Scambia
No relevant relationships to disclose